| Criterion Text | Inclusion/Exclusion | Disease | Biomarker | Prior Therapy | Criterion Rule |
| --- | --- | --- | --- | --- | --- |
| Patients who have castration-resistant disease progression per RECIST in the absence of PSA values rising to >= 1.0ng/ml as per Prostate Cancer Working Group 3 (PCWG3) PSA progression criteria (inclusion--- t) | Inclusion | Prostate cancer | - | - | Patients with castration-resistant prostate cancer and no rising PSA values are included |
| Documented evidence of progressive disease as defined by any of the following: a) PSA progression: minimum of 2 rising values (3 measurements) obtained a minimum of 7 days apart with the last result being at least >= 1.0 ng/mL; b) New or increasing non-bone disease (RECIST); c) Positive bone scan with 2 or more new lesions (Prostate Cancer Working Group 3 [PCWG3]); d) Increasing symptoms unequivocally attributed to disease progression as judged by the treating physician and the principal investigator (PI) | Inclusion | Prostate cancer | - | - | Patients with documented evidence of progressive disease are included |
| Surgically or ongoing medically castrated, with baseline testosterone levels of =< 50 ng/dL (=< 2.0 nM) | Inclusion | Prostate cancer | -